COVID-19 vaccine approved for trials, says Chinese military
The Chinese Ministry of National Defense (MND) announced on 18 March that a vaccine for the COVID-19 coronavirus, developed by the Academy of Military Medical Sciences of the People’s Liberation Army (PLA), has been approved for clinical trials.
The subunit vaccine has apparently been approved for safe testing on humans by an undisclosed (and therefore unverified) third party.
Preparations for mass production of the vaccine are also under way, the MND stated.
The team of PLA scientists worked under senior bioengineer Maj Gen Chen Wei. He has been conducting research in Wuhan, where the COVID-19 outbreak began.
A subunit vaccination includes a fragment of the pathogen that can initiate an immune response.
More from Defence Notes
-
UK faces cost of balancing defensive capabilities abroad as Iran conflict widens
The UK has recently deployed a Type 45 destroyer to Cyprus and has bolstered its presence in the Middle East in recent weeks with supporting air power to protect neighbouring countries’ air defences.
-
White House calls on Pentagon contractors to “rapidly and aggressively” boost weapon production
Intended to sustain Operation Epic Fury against Iran, efforts to increase the production of weapons and ammunition could expose long-standing weaknesses in the US defence industrial base.
-
India’s strategic defence footprint expansion could be accelerated by Iran-Israel conflict
The latest escalation between Iran and Israel could shape New Delhi’s next-generation shield as India deepens cooperation with Israel on missile defence and drone production.
-
Is the US magazine of air defence interceptors deep enough to sustain a long campaign against Iran?
The Pentagon spent a considerable number of THAAD and SM-3 rounds to defend against Iranian missiles in 2025 and has not fully replenished its reserves.
-
New Zealand buys tri-service uncrewed kit from Syos Aerospace
As uncrewed technology continues to play an increasingly central role in modern military activities, New Zealand’s recent acquisitions point towards its the force’s focus on cost-effective capability.